Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), HDAC6 inhibitors(Histone deacetylase 6 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | CN | 30 Jan 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 30 Jan 2022 | |
Stomach Cancer | Phase 2 | CN | 30 Jan 2022 | |
Colonic Cancer | Preclinical | CN | 29 May 2024 | |
Kidney Neoplasms | Preclinical | CN | 29 May 2024 | |
Liver Cancer | Preclinical | CN | 29 May 2024 | |
Lung Cancer | Preclinical | CN | 29 May 2024 |